Histology
Basal Cell Carcinoma
CI-CAN-00000479Explore in graph →
57 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000479Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03610022 | Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1(OPTIVISMO-1) | completed | Phase 4 | 27 | University Hospital, BordeauxOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT00314756 | Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage | completed | Phase 4 | 15 | Wake Forest UniversityOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02436408 | VISmodegib for ORbital and Periocular Basal Cell Carcinoma(VISORB) | completed | Phase 4 | 35 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00847912 | CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial(VAKCCT) | completed | Phase 4 | 954 | VA Office of Research and DevelopmentFED | 1 | Jun 11, 2021 | clinicaltrials |
| NCT00581425 | Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) | completed | Phase 4 | 49 | The University of Texas Health Science Center, HoustonOTHER | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00204555 | Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma | completed | Phase 4 | 100 | University Hospital TuebingenOTHER | 1 | Sep 1, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 19, 2026source: clinicaltrials